Document is current
Any future updates will be listed below
-
Authors
De Giorgi, Ugo
Freedland, Stephen J. https://orcid.org/0000-0002-8104-6419
Rannikko, Antti https://orcid.org/0000-0002-4261-3484
Ramirez-Backhaus, Miguel
Villers, Arnauld
Tarazi, Jamal
Tang, Yiyun
Haas, Gabriel P.
Rosales, Matt
Shore, Neal D. https://orcid.org/0000-0001-5767-0548
-
Funding
Funding for this research was provided by:
Pfizer
Astellas Pharma US
- License Information
-
More Information
Article History
Received: 4 November 2024
Revised: 10 February 2025
Accepted: 24 February 2025
First Online: 26 March 2025
Competing interests
: UDG reports consulting for Amgen, Astellas Pharma Inc., AstraZeneca, Bayer, Bristol Myers Squibb, Esai, Ipsen, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer Inc., and Roche; receiving travel expenses from AstraZeneca, Ipsen, Pfizer Inc., Roche, and Sanofi; and having other financial or non-financial interests in AstraZeneca, Roche, and Sanofi. SJF reports consulting for Astellas Pharma Inc., AstraZeneca, Bayer, Eli Lilly, Exact Sciences, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck, Novartis, Pfizer Inc., Sanofi, and Sumitomo Pharma America, Inc. (formerly Myovant Sciences). AR reports being an advisory board member for Bayer, Johnson & Johnson Innovative Medicine (formerly Janssen), and Orion Pharma; holding a leadership role in the Orion Research Foundation (board chair); and being a member of the board for the Ida Montin Research Foundation. MR-B reports consulting and receiving honoraria from Astellas Pharma Inc., Bayer, and Johnson & Johnson Innovative Medicine (formerly Janssen); receiving payment for expert testimony from Johnson & Johnson Innovative Medicine (formerly Janssen); and receiving travel, accommodation, and expenses from Astellas Pharma Inc. and Johnson & Johnson Innovative Medicine (formerly Janssen). AV reports consulting for Astellas Pharma Inc., AstraZeneca, Ipsen, and Johnson & Johnson Innovative Medicine (formerly Janssen). JT reports being a former employee of and shareholder in Pfizer Inc. YT reports being an employee of and shareholder in Pfizer Inc. GPH reports being an employee of Astellas Pharma Inc.; and stock ownership in Sumitomo Pharma America, Inc. (formerly Myovant Sciences). MR reports being an employee of and shareholder in Astellas Pharma Inc. NDS reports consulting for or receiving research funding from Accord, Alessa Therapeutics, Amgen, Antev, Arquer, Asieris, Astellas Pharma Inc., AstraZeneca, Aura, Bayer, Bristol Myers Squibb, Boston Scientific, CG Oncology (formerly Cold Genesys), Clarity, Clovis Oncology, Dendreon, Eli Lilly, Exact Imaging, Ferring, Fize Medical, Foundation Medicine, GenesisCare US, Guardant Health, Immunitybio, Incyte, InVitae, Johnson & Johnson Innovative Medicine (formerly Janssen), Lantheus, MDxHealth, Merck, Minomic, Myriad, NGM, Nonagen, Novartis, Pfizer Inc., Photocure, PlatformQ, Point Biopharma, Promaxo, Propella, Protara, Sanofi, Specialty Networks, Steba, Sumitomo, Telix, Theralase, Tolmar, Urogen, and Zenflow.
